share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K:外國發行人報告(業績相關)
美股SEC公告 ·  09/26 16:38

Moomoo AI 已提取核心訊息

Alterity Therapeutics Limited, a development stage enterprise, has filed its corporate governance statement for the financial year ended June 30, 2024, with the Securities and Exchange Commission (SEC) as part of its Form 6-K filing for September 2024. The statement, which is current as of September 26, 2024, details the company's compliance with the ASX Corporate Governance Council's recommendations. It includes disclosures on board composition, diversity policy, risk management, and other key governance aspects. The company has chosen to provide this information on its website, with specific URLs given for each section of the corporate governance statement. Alterity Therapeutics has also confirmed that it does not have a nomination committee, instead disclosing the processes it employs to address board succession issues and ensure an appropriate balance of skills and diversity. The company has followed the majority of the recommendations, with detailed disclosures provided for each. The full corporate governance statement is available on Alterity Therapeutics' website, offering transparency to investors and stakeholders regarding the company's governance practices and policies.
Alterity Therapeutics Limited, a development stage enterprise, has filed its corporate governance statement for the financial year ended June 30, 2024, with the Securities and Exchange Commission (SEC) as part of its Form 6-K filing for September 2024. The statement, which is current as of September 26, 2024, details the company's compliance with the ASX Corporate Governance Council's recommendations. It includes disclosures on board composition, diversity policy, risk management, and other key governance aspects. The company has chosen to provide this information on its website, with specific URLs given for each section of the corporate governance statement. Alterity Therapeutics has also confirmed that it does not have a nomination committee, instead disclosing the processes it employs to address board succession issues and ensure an appropriate balance of skills and diversity. The company has followed the majority of the recommendations, with detailed disclosures provided for each. The full corporate governance statement is available on Alterity Therapeutics' website, offering transparency to investors and stakeholders regarding the company's governance practices and policies.
Alterity Therapeutics有限公司是一家發展中的企業,在2024年6月30日結束的財政年度向證券交易委員會(SEC)提交了其公司治理報告,作爲2024年9月份提交的Form 6-k的一部分。該報告截至2024年9月26日,詳細說明了公司遵守澳交所企業治理委員會的建議。其中包括有關董事會構成、多元化政策、風險管理和其他關鍵治理方面的披露。公司選擇在其網站上提供這些信息,爲公司治理報告的每個部分都提供了特定的URL。Alterity Therapeutics還確認公司沒有提名委員會,而是披露了其處理董事會繼任問題和確保技能和多樣性平衡的流程。公司遵循了大部分的建議,爲每一項提供了詳細的披露。Alterity Therapeutics的完整公司治理報告可在其網站上找到,爲投資者和利益相關者提供了關於該公司治理實踐和政策的透明度。
Alterity Therapeutics有限公司是一家發展中的企業,在2024年6月30日結束的財政年度向證券交易委員會(SEC)提交了其公司治理報告,作爲2024年9月份提交的Form 6-k的一部分。該報告截至2024年9月26日,詳細說明了公司遵守澳交所企業治理委員會的建議。其中包括有關董事會構成、多元化政策、風險管理和其他關鍵治理方面的披露。公司選擇在其網站上提供這些信息,爲公司治理報告的每個部分都提供了特定的URL。Alterity Therapeutics還確認公司沒有提名委員會,而是披露了其處理董事會繼任問題和確保技能和多樣性平衡的流程。公司遵循了大部分的建議,爲每一項提供了詳細的披露。Alterity Therapeutics的完整公司治理報告可在其網站上找到,爲投資者和利益相關者提供了關於該公司治理實踐和政策的透明度。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息